JUL 31, 2026 · PHASE 1/2 TRIAL
A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
ClinicalTrials.gov
This is an active clinical trial registry record with no posted results; it describes the planned Phase 1/2 study design and endpoints only.
Reported
Planned enrollment57
Phase 1 primary outcome: Adverse…Up to 2 years 1 month
Phase 1 primary outcome: Dose lim…Cycle 1 (Day 1 through Day 28)